Miconazole%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. This information pertains to a miconazole vaginal pessary, which is a solid dosage form inserted into the vagina. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infection). ## Adult Dosing * **100 mg pessary:** Insert 1 pessary vaginally at bedtime for 7 consecutive nights. * **200 mg pessary:** Insert 1 pessary vaginally at bedtime for 3 consecutive nights. * **100 mg pessary (with applicator):** Insert 1 pessary vaginally at bedtime for 7 consecutive nights. * **200 mg pessary (with applicator):** Insert 1 pessary vaginally at bedtime for 3 consecutive nights. * **Higher strength formulations (e.g., 1200 mg single dose):** Insert 1 pessary vaginally at bedtime as a single dose. Specific dosing and duration may vary based on the product formulation and local protocol. ## Pediatric Dosing The safety and efficacy of miconazole vaginal pessaries in pediatric patients have not been established. Use in pediatric patients is generally not recommended due to lack of data and potential for misuse. ## Dose Adjustments No specific dose adjustments are typically required for renal or hepatic impairment when using vaginal formulations, as systemic absorption is minimal. ## Contraindications * Hypersensitivity to miconazole or any component of the formulation. * Use with CYP3A4 inhibitors (e.g., oral or systemic ketoconazole) due to potential for increased systemic miconazole levels and associated adverse effects, particularly with prolonged or extensive exposure (though risk is low with vaginal use). ## Adverse Effects Common: * Vaginal burning, itching, or irritation. * Pelvic cramps. Less Common: * Headache. * Rash. Rarely, systemic effects can occur, especially with prolonged or extensive use. ## Key Drug Interactions * **CYP3A4 Inhibitors:** Concurrent use of oral or systemic antifungals (like ketoconazole) or other potent CYP3A4 inhibitors may increase systemic miconazole levels. This is of theoretical concern with vaginal use but is a consideration for prolonged or extensive vaginal use. * **Warfarin:** Miconazole (especially oral) can inhibit warfarin metabolism, increasing INR. While systemic absorption from vaginal pessaries is low, caution and INR monitoring may be advised with prolonged or extensive vaginal use, particularly in patients on warfarin. ## Monitoring * Assess for improvement in symptoms of vulvovaginal candidiasis. * Monitor for vaginal irritation or signs of allergic reaction. * Consider INR monitoring if patient is on warfarin and using miconazole vaginally for an extended duration, though the risk of significant interaction is low. ## Clinical Pearls * Instruct patients on proper insertion technique to ensure efficacy. * Advise patients to complete the full course of treatment, even if symptoms improve sooner. * Avoid intercourse during treatment. * Miconazole can weaken latex condoms and diaphragms, reducing their effectiveness. --- *This information is intended for healthcare professionals. Always verify current prescribing information with the official product labeling and consider individual patient factors.*